News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
CHL is strengthening its play in the fast-growing beauty and personal care sector
Fluid bed processes: drying, granulating, and coating in just one product container
Subscribe To Our Newsletter & Stay Updated
